Background: Ranolazine decreases the frequency of arrhythmias during the acute phases of ischemic heart disease (IHD), but it remains unknown if it has similar effects in the chronic phase of the disease. We performed a prospective, randomized, cross-over pilot trial to test the hypothesis that chronic treatment with ranolazine can reduce the incidence of documented arrhythmias and the related symptoms of palpitation in stable patients with IHD.
improves clinical outcomes through salvage of myocardial tissue. Although use of thrombus aspiration with PCI can improve epicardial flow and myocardial perfusion, several unmet needs remain. The purpose of this trial was to evaluate the hypothesis that local delivery of low-dose thrombolytics can enhance the efficacy of thrombus aspiration in STEMI patients undergoing primary PCI.
Methods: A total of 102 patients with STEMI and angiographic evidence of totally occlusive thrombosis in the culprit artery were randomly assigned to receive local bolus of 200,000 units urokinase (N = 51) or saline solution (N = 51) followed by manual aspiration thrombectomy (Pronto™, Vascular Solutions, Inc., Minneapolis, Minnesota) and PCI. Both groups received abciximab (i.v. bolus + 12-h infusion). End points included final thrombolysis in myocardial infarction (TIMI) flow grade, frame count, and thrombus grade N 2, myocardial blush grade (MBG), 60-min ST-segment resolution (STR) N 70%, and 6-month clinical outcomes. All patients had echocardiography at 6-month and left ventricular ejection fraction (EF) and wall motion score (WMS) were obtained.
Results: Baseline clinical and angiographic characteristics of both groups were similar. Local urokinase was associated with post-PCI evidence of higher TIMI flow grade 3 (96% vs. 68%; p = 0.027), lower TIMI frame count (18 ± 11 vs. 25 ± 13; p = 0.045) and fewer TIMI thrombus grade N 2 (20% vs. 52%; p = 0.039). Histopathologic evaluation performed in 11 Gr. A and 11 Gr. B patients showed that aspirated thrombi after urokinase were smaller, softer and less organized than after saline. Post-PCI myocardial perfusion was slightly increased with urokinase (MBG 2/3: 88% vs. 64%; p = 0.09), with significantly more patients showing STR N 70% (80% vs 56%, p = 0.001). No differences between the two groups were subsequently seen in clinical outcomes and EF, whereas 6-month WMS was significantly lower in patients receiving local urokinase than saline (1.21 ± 0.29 vs 1.45 ± 0.32, p = 0.008).
Conclusion: Local delivery of low-dose thrombolytics before thrombectomy in STEMI patients undergoing primary PCI is associated with improved coronary flow, myocardial perfusion, and 6-month regional myocardial function. Delivery of low-dose thrombolytic agents directly to the site of thrombus might be an effective strategy to enhance efficacy of thrombus aspiration in primary PCI. Pharmacodynamic effects of atorvastatin vs. rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy -The PEARL randomized cross-over study Francesco Pelliccia, Giuseppe Marazzi, Vincenzo Pasceri, Marina Polacco, Luigi Mattioli, Cesare Greco, Carlo Gaudio Department of Cardiology, University of Rome "La Sapienza", Italy Background: Levels of platelet reactivity in patients on dual antiplatelet therapy (DAPT) can potentially be influenced by concomitant treatment with statins that inhibit the CYP3A4 system involved in the activation of clopidogrel. Recent studies have shown that a high platelet reactivity during co-administration of clopidogrel and a CYP3A4-metabolized statin (i.e. atorvastatin) can be lowered by switching to a non-CYP3A4-metabolized statin (i.e. rosuvastatin). Aim of this study was to verify if atorvastatin and rosuvastatin have different pharmacodynamic effects also when they are given to patients with coronary artery disease (CAD) with baseline normal platelet reactivity while on DAPT.
Methods: A total of 100 stable CAD patients receiving DPAT (clopidogrel 75 mg plus aspirin 100 mg) who had evidence of normal Abstracts 8
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